Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Tuesday.
A number of other analysts also recently issued reports on FOLD. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Friday, August 9th. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 price target on the stock. JPMorgan Chase & Co. dropped their price target on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a report on Friday, August 16th. Morgan Stanley dropped their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Friday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price objective on shares of Amicus Therapeutics in a research note on Friday, September 20th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Amicus Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $16.88.
View Our Latest Stock Report on Amicus Therapeutics
Amicus Therapeutics Stock Performance
Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The company had revenue of $126.67 million for the quarter, compared to the consensus estimate of $121.21 million. During the same period in the prior year, the firm posted ($0.15) EPS. Amicus Therapeutics’s revenue for the quarter was up 34.0% on a year-over-year basis. Sell-side analysts expect that Amicus Therapeutics will post -0.07 EPS for the current fiscal year.
Insider Buying and Selling at Amicus Therapeutics
In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total transaction of $87,825.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $10,382,718.34. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold a total of 22,500 shares of company stock valued at $244,875 in the last three months. 2.20% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Amicus Therapeutics
Institutional investors have recently added to or reduced their stakes in the stock. Headlands Technologies LLC purchased a new position in shares of Amicus Therapeutics in the second quarter valued at $89,000. Sage Capital Advisors llc purchased a new position in shares of Amicus Therapeutics in the second quarter valued at $103,000. Sanctuary Advisors LLC purchased a new position in shares of Amicus Therapeutics in the second quarter valued at $138,000. EntryPoint Capital LLC grew its holdings in shares of Amicus Therapeutics by 278.8% in the first quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock valued at $156,000 after purchasing an additional 9,729 shares in the last quarter. Finally, Xponance Inc. grew its holdings in shares of Amicus Therapeutics by 5.3% in the second quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 936 shares in the last quarter.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Featured Stories
- Five stocks we like better than Amicus Therapeutics
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- How Investors Can Find the Best Cheap Dividend Stocks
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- Upcoming IPO Stock Lockup Period, Explained
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.